Clinical Trials
Ascletis Completes Enrollment for Phase III Trial of ASC40 in Acne
Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 Ascletis Pharma Inc. ann...
November 13, 2024 | News
Alphamab Oncology’s JSKN033 Receives Fast-Track Approval from Shanghai Drug Authority for Innovative Cancer Therapy Clinical Trials
Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulatio...
November 13, 2024 | News
Nordic Bioscience Secures FDA Letter of Support for CPa9-HNE Biomarker in Advancing IBD Clinical Trials
Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS) from the U.S. Food and Drug ...
November 12, 2024 | News
China’s Gan & Lee’s GZR18 Injection Achieves Up to 17.8% Weight Loss in Phase 2b Trial
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean ...
November 12, 2024 | News
Harbour BioMed Files IND Application in China for Novel Antibody Therapy HBM9378/SKB378 Targeting COPD
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...
November 11, 2024 | News
Dizal Submits NDA to U.S. FDA for Sunvozertinib as a New Treatment Option for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announ...
November 11, 2024 | News
Aditum Bio and Leads Biolabs Launch Oblenio Bio to Advance First-in-Class Tri-Specific Antibody for Autoimmune Diseases
Aditum Bio and Leads Biolabs announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreeme...
November 08, 2024 | News
Ascletis' ASC47 Shows Promise in Phase I Trial with Once-Monthly Dosing and Superior Fat Reduction in Obesity Treatment
Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed...
November 08, 2024 | News
Minghui Pharmaceutical Announces Promising Phase I Results for MHB039A, a PD-1 x VEGF Bispecific Antibody, in Solid Tumor Treatment in China
Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today annou...
November 07, 2024 | News
China’s Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody target...
November 07, 2024 | News
Medidata Introduces Oncology and Vaccine Solutions to Streamline Phase II and III Trials with FDA-Aligned Patient-Centric Design
The new products combine Medidata's diverse technologies and experience from thousands of previous trials to streamline the management of Phase II an...
November 05, 2024 | News
Chipscreen Biosciences Secures NMPA Approval for Phase III Trial of Chiauranib in ES-SCLC Treatment
Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Ph...
November 04, 2024 | News
Hong Kong's Akeso Biopharma Advances Immunotherapy in Biliary Tract Cancer with First Patient Enrolled in Phase III Study of Ivonescimab
Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, c...
November 01, 2024 | News
Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy
Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...
October 31, 2024 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
Editor Picks
